Last updated: 11/03/2018 20:31:57
Completed clinical study under GSK sponsorship. The product that is studied in this clinical study, together with the rights to the data and results generated, has been transferred by GSK to Pfizer. GSK’s Clinical Study Register is no longer maintained for this study. To request access to clinical study data from Pfizer, go here: http://www.pfizer.com/research/clinical_trials/trial_data_and_results

Study to evaluate meningococcal serogroups A,C,W-135,Y conjugate vaccine when given as 1 dose to healthy subjects aged 18-25 years

Request patient level data
GSK study ID
134612/003
See study documents
Clinicaltrials.gov ID
NCT00196950
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Assess the safety, reactogenicity, immunogenicity & long-term persistence of one intramuscular dose of GSK Biologicals' MenACWY conjugate vaccine vs one subcutaneous dose of Mencevax™ ACWY in healthy adults aged 18-25 yrs
Trial description: The purpose of this study is to evaluate the safety, reactogenicity, immunogenicity and persistence up to three years after administration of one dose of the MenACWY conjugate vaccine when given to young adults aged 18-25 years.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Biological/vaccine: Meningococcal (vaccine)
Enrollment:
50
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Østergaard L et al. (2009) Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years. Vaccine. 27(1):161-168
Medical condition
Infections, Meningococcal
Product
GSK134612A
Collaborators
Not applicable
Study date(s)
September 2003 to October 2003
Type
Interventional
Phase
2

Participation criteria

Sex
Female & Male
Age
18 - 25 years
Accepts healthy volunteers
Yes
  • Healthy male or female between, and including, 18 and 25 years of age at the time of vaccination.
  • Written informed consent obtained.
  • Previous vaccination against OR history of OR exposure within previous 12 months to, meningococcal serogroup A, C, W-135 or Y disease.
  • Administration of a tetanus vaccine within 6 months before study vaccination.
Inclusion and exclusion criteria
Inclusion criteria:
  • Healthy male or female between, and including, 18 and 25 years of age at the time of vaccination.
  • Written informed consent obtained.
  • Subject with previously completed routine childhood vaccinations to the best of his/her knowledge.
  • Female subjects should be of non-childbearing potential, or abstinent, or using an adequate contraception.
Exclusion criteria:
  • Previous vaccination against OR history of OR exposure within previous 12 months to, meningococcal serogroup A, C, W-135 or Y disease.
  • Administration of a tetanus vaccine within 6 months before study vaccination.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
  • A family history of congenital or hereditary immunodeficiency.
  • History of any neurologic disorders or seizures.
  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • History of chronic alcohol consumption and/or drug abuse

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Gosselies, Belgium, 6041
Status
Study Complete
Contact us

Study documents

Clinical study report
Available language(s): English
Download document(s)
Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
No longer a GSK study
Actual primary completion date
Not applicable
Actual study completion date
2003-25-10

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click here
Access to clinical trial data by researchers
Visit website